<p>The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at the state-run Sassoon General Hospital here in Maharashtra on Monday, a senior official said.</p>.<p>"We have started the phase-III trials of the vaccine (candidate Covishield). We will administer dose to 150 to 200 volunteers," said Dr Muralidhar Tambe, Dean, Sassoon General Hospital.</p>.<p>Under phase-II, trials had been conducted at the Bharti Vidyapeeth Medical College and also KEM Hospital in the city.</p>.<p>The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, being developed by the University of Oxford.</p>.<p>Earlier this month, the SII had paused the clinical trials of the vaccine candidate in the country.</p>.<p>The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of "an unexplained illness" in a participant in the study.</p>.<p>However, on September 15, the DCGI gave permission to the SII to resume clinical trial of the vaccine.</p>
<p>The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at the state-run Sassoon General Hospital here in Maharashtra on Monday, a senior official said.</p>.<p>"We have started the phase-III trials of the vaccine (candidate Covishield). We will administer dose to 150 to 200 volunteers," said Dr Muralidhar Tambe, Dean, Sassoon General Hospital.</p>.<p>Under phase-II, trials had been conducted at the Bharti Vidyapeeth Medical College and also KEM Hospital in the city.</p>.<p>The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, being developed by the University of Oxford.</p>.<p>Earlier this month, the SII had paused the clinical trials of the vaccine candidate in the country.</p>.<p>The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of "an unexplained illness" in a participant in the study.</p>.<p>However, on September 15, the DCGI gave permission to the SII to resume clinical trial of the vaccine.</p>